Cardiology

Back to articles

Aspirin Holds Own in Comparison with Glycoprotein IIb/IIIa Inhibitor

KEY POINT

For prevention of further coronary events in patients with unstable angina or myocardial infarction, the glycoprotein IIb/IIIa inhibitor sibrafiban (Xubix—Roche) provides no additional benefit over aspirin alone.

SOURCES

The SYMPHONY Investigators. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. Lancet. 2000;355:337–45.

Heeschen C, Hamm CW. Difficulties with oral platelet glycoprotein IIb/IIIa receptor antagonists [editorial]. Lancet. 2000;355:330.